CureVac Pulls Covid Vaccine from Review to Focus on Second-Generation Program

• (PLX AI) - CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
• • CureVac to withdraw its first-generation COVID-19 vaccine candidate from regulatory review
• • COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK
• • Expects second-generation vaccine to progress to late-stage clinical development by Q2 2022
• • CureVac says joint development focuses on optimized second-generation mRNA vaccines that offer the potential to target different COVID-19 variants, the ability to address different diseases in a combination shot and improved vaccine administration formats